ITOC 2022 | Overcoming the challenges faced with cellular therapies in solid tumors

Sebastian Kobold, MD, PhD, Ludwig-Maximilians-Universität München, Munich, Germany, discusses key issues faced when applying cellular therapies to solid tumors including access to tumor tissue, T-cell engagement and heterogeneity of antigen expression. To mitigate these challenges, modular platforms can be used to selectively target cancer cells to allow control over T-cell activity and to target multiple antigens simultaneously with a single T-cell. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved